📊 SRRK Key Takeaways
Is Scholar Rock Holding Corp (SRRK) a Good Investment?
Scholar Rock is a clinical-stage biopharmaceutical company with zero revenue and operating losses of $384.6M, burning $300.6M annually in free cash flow. Despite a strong cash position of $323.5M providing approximately 1 year of runway, the lack of commercial revenue, massive operating losses, and inability to sustain operations without significant clinical success represent fundamental weaknesses.
Why Buy Scholar Rock Holding Corp Stock? SRRK Key Strengths
- Strong cash position of $323.5M provides near-term liquidity for R&D and operations
- Excellent current ratio of 6.95x indicates strong short-term financial flexibility
- Manageable leverage with debt-to-equity ratio of 0.41x and reasonable capital structure
SRRK Stock Risks: Scholar Rock Holding Corp Investment Risks
- Zero revenue with -100% YoY decline indicates loss of commercial revenue or failed product commercialization
- Operating cash burn of $300.6M annually with only ~1 year of runway at current rates without additional capital
- Massive operating losses of $384.6M with negative ROE (-154%) and ROA (-93.5%) demonstrate unsustainable operations
- Clinical-stage execution risk: company entirely dependent on successful drug development and regulatory approval
- Will require additional capital raise or immediate profitability to avoid cash depletion
Key Metrics to Watch
- Operating cash flow trajectory and burn rate reduction
- Achievement of clinical milestones and regulatory progress on pipeline candidates
- Revenue generation from potential product commercialization or licensing deals
Scholar Rock Holding Corp (SRRK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.95x current ratio provides a solid financial cushion.
SRRK Profit Margin, ROE & Profitability Analysis
SRRK vs Healthcare Sector: How Scholar Rock Holding Corp Compares
How Scholar Rock Holding Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scholar Rock Holding Corp Stock Overvalued? SRRK Valuation Analysis 2026
Based on fundamental analysis, Scholar Rock Holding Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scholar Rock Holding Corp Balance Sheet: SRRK Debt, Cash & Liquidity
SRRK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scholar Rock Holding Corp's revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-2.47 indicates the company is currently unprofitable.
SRRK Revenue Growth, EPS Growth & YoY Performance
SRRK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$56.9M | $-0.66 |
| Q2 2025 | N/A | -$56.9M | $-0.60 |
| Q3 2023 | $33.2M | -$8.0M | $-0.53 |
| Q2 2023 | $33.2M | -$8.0M | $-0.47 |
| Q1 2023 | $33.2M | -$8.0M | $-0.21 |
| Q3 2022 | $5.5M | -$8.0M | $-0.55 |
| Q2 2022 | $4.6M | -$8.0M | $-0.84 |
| Q1 2022 | $4.7M | -$8.0M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scholar Rock Holding Corp Dividends, Buybacks & Capital Allocation
SRRK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scholar Rock Holding Corp (CIK: 0001727196)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRRK
What is the AI rating for SRRK?
Scholar Rock Holding Corp (SRRK) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRRK's key strengths?
Claude: Strong cash position of $323.5M provides near-term liquidity for R&D and operations. Excellent current ratio of 6.95x indicates strong short-term financial flexibility.
What are the risks of investing in SRRK?
Claude: Zero revenue with -100% YoY decline indicates loss of commercial revenue or failed product commercialization. Operating cash burn of $300.6M annually with only ~1 year of runway at current rates without additional capital.
What is SRRK's revenue and growth?
Scholar Rock Holding Corp reported revenue of $0.0.
Does SRRK pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
Where can I find SRRK SEC filings?
Official SEC filings for Scholar Rock Holding Corp (CIK: 0001727196) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRRK's EPS?
Scholar Rock Holding Corp has a diluted EPS of $-3.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRRK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Scholar Rock Holding Corp has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRRK stock overvalued or undervalued?
Valuation metrics for SRRK: ROE of -154.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SRRK stock in 2026?
Our dual AI analysis gives Scholar Rock Holding Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRRK's free cash flow?
Scholar Rock Holding Corp's operating cash flow is $-300.0M, with capital expenditures of $602.0K.
How does SRRK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -154.0% (avg: 15%), current ratio 6.95 (avg: 2).